Business Description
Pharos IBio Co Ltd
ISIN : KR7388870008
Compare
Compare
Traded in other countries / regions
388870.Korea IPO Date
2023-07-27Description
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 83.58 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 24.8 | |||||
| 3-Year EPS without NRI Growth Rate | 26.2 | |||||
| 3-Year FCF Growth Rate | 11.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.02 | |||||
| 9-Day RSI | 41.97 | |||||
| 14-Day RSI | 44.3 | |||||
| 6-1 Month Momentum % | 57.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 21.57 | |||||
| Quick Ratio | 21.57 | |||||
| Cash Ratio | 21.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -31.7 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -29 | |||||
| ROA % | -27.69 | |||||
| ROIC % | -222.56 | |||||
| ROC (Joel Greenblatt) % | -239.8 | |||||
| ROCE % | -28.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 6.52 | |||||
| Price-to-Tangible-Book | 6.77 | |||||
| EV-to-EBIT | -24.76 | |||||
| EV-to-EBITDA | -26.82 | |||||
| EV-to-FCF | -53.75 | |||||
| Price-to-Net-Current-Asset-Value | 7.68 | |||||
| Price-to-Net-Cash | 7.9 | |||||
| Earnings Yield (Greenblatt) % | -4.04 | |||||
| FCF Yield % | -1.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pharos IBio Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | |||
| EPS (TTM) (â‚©) | -538.386 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 44.3 | ||
| 14-Day ATR (â‚©) | 986.447522 | ||
| 20-Day SMA (â‚©) | 15150.5 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (â‚©) | 9510 - 25000 | ||
| Shares Outstanding (Mil) | 12.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pharos IBio Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pharos IBio Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pharos IBio Co Ltd Frequently Asked Questions
What is Pharos IBio Co Ltd(XKRX:388870)'s stock price today?
The current price of XKRX:388870 is â‚©14770.00. The 52 week high of XKRX:388870 is â‚©25000.00 and 52 week low is â‚©9510.00.
When is next earnings date of Pharos IBio Co Ltd(XKRX:388870)?
The next earnings date of Pharos IBio Co Ltd(XKRX:388870) is .
Does Pharos IBio Co Ltd(XKRX:388870) pay dividends? If so, how much?
Pharos IBio Co Ltd(XKRX:388870) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers